Zevra Therapeutics
7 Hawkeye Drive
Suite 103
North Liberty
Iowa
52317
United States
Tel: 319-665-2575
Fax: 319-665-2577
Website: http://www.kempharm.com/
Email: info@kempharm.com
237 articles about Zevra Therapeutics
-
Zevra Therapeutics to Report 2023 Fourth Quarter and Full Year Financial Results on March 28, 2024
3/18/2024
Zevra Therapeutics, Inc. today announced that it will host a conference call and live audio webcast on Thursday, March 28, 2024, at 4:30 p.m. ET, to review its corporate and financial results for the fourth quarter and full year 2023.
-
Zevra Therapeutics Provides FDA Update on the PDUFA Action Date for Arimoclomol as a Treatment for Niemann-Pick Disease Type C
3/4/2024
Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for arimoclomol, an investigational orally delivered, first-in-class treatment for Niemann-Pick disease type C (NPC).
-
Zevra Therapeutics to Participate at Upcoming Investor Conferences
2/28/2024
Zevra Therapeutics, Inc. today announced that Neil F. McFarlane, President and Chief Executive Officer of Zevra, will present at upcoming investor conferences in March 2024.
-
Zevra Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
2/6/2024
Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced that it will present at the upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference being held virtually on Tuesday, February 13, 2024, at 9:20 a.m. ET.
-
Zevra Therapeutics Appoints Experienced Biopharma Executive Alvin Shih, MD, MBA, to the Board of Directors
1/23/2024
Zevra Therapeutics, Inc. today announced the appointment of Alvin Shih, MD, MBA, to the Company’s Board of Directors (Board) effective as of January 20, 2024.
-
Zevra Therapeutics Receives FDA Acceptance of Resubmission of NDA for Arimoclomol as a Treatment for Niemann-Pick Disease Type C
1/8/2024
Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the resubmission of the New Drug Application (NDA) for arimoclomol as an orally-delivered, first-in-class treatment for Niemann-Pick disease type C.
-
Zevra Therapeutics Appoints Global Medical Leader, Adrian Quartel, M.D., FFPM, as Chief Medical Officer
1/4/2024
Zevra Therapeutics, Inc. today announced the appointment of Adrian Quartel, M.D., FFPM, as Chief Medical Officer.
-
Zevra Therapeutics Announces Resubmission of Arimoclomol New Drug Application to the U.S. Food and Drug Administration
12/27/2023
Zevra Therapeutics, Inc. a rare disease therapeutics company, announced it resubmitted its New Drug Application for arimoclomol, an investigational therapeutic candidate for the treatment of Niemann-Pick disease type C to the U.S. Food and Drug Administration on December 22, 2023.
-
Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company
11/20/2023
Zevra Therapeutics, Inc. today announced the completion of its acquisition of Acer Therapeutics Inc.
-
Zevra Therapeutics Reports Corporate Updates and Third Quarter 2023 Financial Results
11/7/2023
Zevra Therapeutics, Inc., a rare disease therapeutics company, provided corporate updates and reported its financial results for the quarter ended September 30, 2023.
-
Zevra Therapeutics to Report Third Quarter 2023 Results on November 7, 2023, at 8:00 a.m. ET
10/31/2023
Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company) a rare disease therapeutics company, today announced that it will host a conference call and live audio webcast on Tuesday, November 7, 2023, at 8:00 a.m. ET, to review its corporate and financial results for the third quarter of 2023.
-
Zevra Therapeutics Celebrates and Supports Global Niemann-Pick Disease Awareness Day on October 19th and Niemann-Pick Disease Awareness Month Throughout October
10/19/2023
Zevra Therapeutics, Inc. (NasdaqGS: ZVRA), a rare disease therapeutics company, proudly supports the Niemann-Pick community on Global Niemann-Pick Disease Awareness Day and throughout Niemann-Pick Disease Awareness Month.
-
Zevra Therapeutics Appoints Neil F. McFarlane as President, Chief Executive Officer and Director
10/10/2023
Zevra Therapeutics, Inc. today announced that Neil F. McFarlane has been named President and Chief Executive Officer of Zevra and appointed to the Board of Directors, effective October 10, 2023.
-
Zevra Therapeutics to Present at the 52nd Child Neurology Society Annual Meeting
10/5/2023
Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that it will present data related to clinical study outcomes and its early access programs via both oral and poster presentations at the upcoming 52 nd Child Neurology Society (CNS) Annual Meeting.
-
Zevra Therapeutics Announces Interim Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia
10/2/2023
Zevra Therapeutics, Inc. announced interim data from the open-label dose titration phase of the Phase 2 clinical trial evaluating KP1077 in patients with idiopathic hypersomnia (IH).
-
Zevra Therapeutics to Participate in the Cantor Global Healthcare Conference
9/20/2023
Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that executive management will participate in a fireside chat at the Cantor Global Healthcare Conference on Wednesday, September 27, 2023, at 3:00 p.m. ET.
-
Zevra Therapeutics Presents Full Data Set on the Cardiovascular Safety and Pharmacokinetics of SDX, the sole API in KP1077, in Healthy Volunteers at Psych Congress 2023
9/10/2023
Zevra Therapeutics, Inc., a rare disease therapeutics company, announced a poster presentation featuring study data that underscores the cardiovascular safety profile of serdexmethylphenidate, the sole active pharmaceutical ingredient in KP1077, Zevra’s investigational candidate for the treatment for idiopathic hypersomnia, at the Psych Congress 2023 taking place September 6-10, 2023, in Nashville, Tennessee.
-
Zevra Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
9/5/2023
Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that executive management will present at the H.C. Wainwright 25th Annual Global Investment Conference on Wednesday, September 13, 2023, at 8:30 a.m. ET.
-
Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product
8/31/2023
Zevra Therapeutics, Inc. and Acer Therapeutics Inc. announced the companies have entered into a definitive agreement pursuant to which Zevra would acquire Acer in a merger transaction having a total potential value for Acer stockholders of up to $91 million.
-
Zevra Therapeutics Reports Corporate Updates and Second Quarter 2023 Financial Results
8/14/2023
Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today provided corporate updates and reported its financial results for the quarter ended June 30, 2023.